Volume 76, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


We used logistic regression to assess effectiveness of primaquine as anti-relapse therapy using data extracted from studies of relapses in Brazil, India, and Thailand. The risk of relapse in Thailand was 10 times that in India and twice that in Brazil. In comparison with no primaquine treatment, the risk of relapse decreased by approximately 80% for a total adult primaquine regimen of 210 mg and by ≥95% for regimens of 315 mg and 420 mg. In addition, we used logistic regression to estimate the risk of relapse according to weight-based primaquine dose using data from case studies. There was a three-fold increase in the likelihood of successful treatment of each additional milligram of primaquine per kilogram of body weight. Tailoring primaquine therapy to a region requires consideration of factors including body weight, natural relapse rates, and local response to primaquine.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 (Suppl 1–2): 97–106. [Google Scholar]
  2. Bray RS, Garnham PC, 1982. The life-cycle of primate malaria parasites. Br Med Bull 38 : 117–122. [Google Scholar]
  3. Cogswell FB, 1992. The hypnozoite and relapse in primate malaria. Clin Microbiol Rev 5 : 26–35. [Google Scholar]
  4. Baird JK, Rieckmann KH, 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19 : 115–120. [Google Scholar]
  5. Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39 : 1336–1345. [Google Scholar]
  6. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T, 1994. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 88 : 218–219. [Google Scholar]
  7. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA, 1999. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 93 : 809–812. [Google Scholar]
  8. Coatney RG, Cooper WC, Young MD, 1950. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J National Malaria Soc 9 : 381–396. [Google Scholar]
  9. Coatney GR, Alving AS, Jones R, Hankey DD, Robinson DH, Garrison PL, Coker WG, Donovan WN, Di Lorenzo A, Marx RL, Simmons IH, 1953. Korean vivax malaria V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg 6 : 985–988. [Google Scholar]
  10. Alving AS, Hankey DD, Coatney GR, Jones R, Coker WG, Garrison PL, Donovan WN, 1953. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 6 : 970–976. [Google Scholar]
  11. Clyde DF, McCarthy VC, 1977. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 26 : 562–563. [Google Scholar]
  12. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL, 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46 : 301–306. [Google Scholar]
  13. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, 1960. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerthrocytic forms of the Chesson strain of Plasmodium vivax by intermittant regimens of drug administration. Bull World Health Organ 22 : 621–631. [Google Scholar]
  14. Dua VK, Sharma VP, 2001. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. Ann Trop Med Parasitol 95 : 655–659. [Google Scholar]
  15. Smoak BL, DeFraites RF, Magill AJ, Kain KC, Wellde BT, 1997. Plasmodium vivax infections in U.S. army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 56 : 231–234. [Google Scholar]
  16. Rowland M, Durrani N, 1999. Randomized controlled trials of 5-and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg 93 : 641–643. [Google Scholar]
  17. Duarte EC, Pang LW, Ribeiro LC, Fernandes Fontes CJ, 2001. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 65 : 471–476. [Google Scholar]
  18. Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH, 2000. In-vivo sensitivity of Plasmodium vivax isolates from Rondonia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Ann Trop Med Parasitol 94 : 749–758. [Google Scholar]
  19. Rajgor DD, Gogtay NJ, Kadam VS, Kamtekar KD, Dalvi SS, Chogle AR, Aigal U, Bichile LS, Kain KC, Kshirsagar NA, 2003. Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Trans R Soc Trop Med Hyg 97 : 438–440. [Google Scholar]
  20. Yadav RS, Ghosh SK, 2002. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. J Parasitol 88 : 1042–1044. [Google Scholar]
  21. Srivastava HC, Sharma SK, Bhatt RM, Sharma VP, 1996. Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. Indian J Malariol 33 : 173–179. [Google Scholar]
  22. Adak T, Valecha N, Sharma VP, 2001. Plasmodium vivax polymorphism in a clinical drug trial. Clin Diag Lab Immunol 8 : 891–894. [Google Scholar]
  23. Mehrunnisa A, Wajihullah, Saifi MA, Khan HM, 2002. Prevalance of malaria in Aligarh. J Comm Dis 34 : 70–77. [Google Scholar]
  24. Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar NA, 1998. A 5 days primaquine regimen as antirelapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg 92 : 341. [Google Scholar]
  25. Gogtay N, Desai S, Kadam VS, Kamtekar KD, Dalvi SS, Kshirsagar NA, 2000. Relapse pattern of Plasmodium vivax in Mumbai: A study of 283 cases of vivax malaria. J Assoc Physicians India 48 : 1085–1086. [Google Scholar]
  26. Looareesuwan S, Wilairatana P, Glanarongran R, Indravijit KA, Supeeranontha L, Chinnapha S, Scott TR, Chulay JD, 1999. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 93 : 637–640. [Google Scholar]
  27. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F, 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 93 : 433–438. [Google Scholar]
  28. Walsh DS, Wilairatana P, Tang DB, Heppner DG, Brewer TG, Krudsood S, Silachamroon U, Phumratnaprapin W, Siriyanonda D, Looareesuwan S, 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 39 : 1095–1103. [Google Scholar]
  29. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ, 1994. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169 : 932–935. [Google Scholar]
  30. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M, 2004. Compliance with 14-day primaquine therapy for radical cure of vivax malaria: a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 98 : 168–173. [Google Scholar]
  31. Kitchener SJ, Seidl I, 2002. Relapsing vivax malaria. Med J Aust 176 : 502. [Google Scholar]
  32. Luzzi GA, Warrell DA, Barnes AJ, Dunbar EM, 1992. Treatment of primaquine-resistant Plasmodium vivax malaria. Lancet 340 : 310. [Google Scholar]
  33. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon A, Walsh DS, 1997. Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 91 : 939–943. [Google Scholar]
  34. Signorini L, Matteelli A, Castelnuovo F, Castelli F, Oladeji O, Carosi G, 1996. Short report: Primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala. Am J Trop Med Hyg 55 : 472–473. [Google Scholar]
  35. Gascon J, Gomez Arce JE, Menendez C, Valls ME, Corachan M, 1994. Poor response to primaquine in two cases of Plasmodium vivax malaria from Guatemala. Trop Geogr Med 46 : 32–33. [Google Scholar]
  36. Schwartz E, Regev-Yochay G, Kurnik D, 2000. Short report: A consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 62 : 393–395. [Google Scholar]
  37. StataCorp, 2002. STATA™ Statistics/Data Analysis. College Station, TX: Stata Corporation.
  38. Bouma MJ, Goris M, Akhtar T, Khan N, Khan N, Kita E, 1995. Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and Afghan refugee communities in Pakistan: implications for the use of primaquine in regional malaria control programmes. Trans R Soc Trop Med Hyg 89 : 62–64. [Google Scholar]
  39. Kron MA, 1996. Substandard primaquine phosphate for US Peace Corps personnel. Lancet 348 : 1453–1454. [Google Scholar]

Data & Media loading...

  • Received : 14 Aug 2006
  • Accepted : 24 Oct 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error